Literature DB >> 24770811

Seroprevalence of serum HBsAg positivity and hepatitis delta virus infection among blood donors in Southeastern Turkey.

S Mese1, S Nergiz1, S Tekes2, K Gul1.   

Abstract

AIMS: HBV and HDV infection is still a serious health problem in Southeastern Turkey. In this study, we aim to investigate the prevalence serum HBsAg along with HDV infection among volunteer blood donors.
MATERIALS AND METHODS: This single centre and prospective study was performed in 6200 consecutive volunteer blood donors admitted to the Central Blood Bank of Dicle University Hospital. All adult blood donors included males and females were screened for HBsAg positivity. The positive serum samples for HBsAg were assessed for total anti-delta antibodies using the micro-ELISA method. Serum samples of anti-delta antibody positive cases were then examined for the presence of serum HDV RNA by real time, reverse transcription PCR method.
RESULTS: Six thousand two hundred adult volunteer blood donors were enrolled to the study. Of all analyzed blood donors, 6004 (96.8%) were men and 196 (3.2%) were women. Serum HBsAg positivity was found in 3% (186/6200) of 6200 blood donors. The mean age and female/male ratio of HBsAg positive cases (n=186) were 32.85±10.04 years and 12/174, respectively. Serum anti-delta antibodies were detected in 6.98% (13/186) of HBsAg positive cases. The mean age of anti-delta antibody positive cases (n=13) was 44.5±13.61 years and female/male ratio was 1/12. Moreover, 2 cases, (15.39%, 2/13) that were positive for anti-delta antibody, had serum HDV RNA positivity.
CONCLUSIONS: It would be appropriate for HBsAg positive volunteer blood donors to be assessed regarding concurrent HDV infection as well. The magnitude of the contribution and benefit that this screening would provide to our region, which is endemic for HDV infection, is the early diagnosis and management of this devastating disease. The real viremia in these cases can be best shown by using sensitive real time PCR method for the presence of serum HDV RNA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24770811     DOI: 10.7471/CT.2014.1683

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  7 in total

1.  Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes.

Authors:  Tatyana Kushner; Marina Serper; David E Kaplan
Journal:  J Hepatol       Date:  2015-05-08       Impact factor: 25.083

2.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

3.  The prevalence and impact of brucellosis in patients with hepatitis delta virus infection: inside the Brucella outbreak with cirrhosis.

Authors:  Burak Suvak; Ahmet Cumhur Dulger; Ozlem Suvak; Aysun Özel Yesilyurt; Bilge Gultepe; Huseyin Guducuoglu
Journal:  Arch Med Sci       Date:  2017-01-20       Impact factor: 3.318

4.  Global Distribution and Natural Recombination of Hepatitis D Virus: Implication of Kyrgyzstan Emerging HDVs in the Clinical Outcomes.

Authors:  Amina Nawal Bahoussi; Pei-Hua Wang; Yan-Yan Guo; Nighat Rabbani; Changxin Wu; Li Xing
Journal:  Viruses       Date:  2022-07-02       Impact factor: 5.818

Review 5.  A Review of HDV Infection.

Authors:  Gian Paolo Caviglia; Alessia Ciancio; Mario Rizzetto
Journal:  Viruses       Date:  2022-08-10       Impact factor: 5.818

Review 6.  The HBsAg Prevalence Among Blood Donors From Eastern Mediterranean and Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Mehran Babanejad; Neda Izadi; Farid Najafi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-03-26       Impact factor: 0.660

Review 7.  Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic.

Authors:  Caterina Sagnelli; Mariantonietta Pisaturo; Caterina Curatolo; Alessio Vinicio Codella; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.